
Trump's Tariff Plan Sparks Sharp Drop in Indian Pharma Stocks
The story in brief
Indian pharmaceutical stocks fell sharply after Trump announced a phased tariff plan on generic medicines, with Cipla and Dr Reddy’s Laboratories dropping 1.8% and 1.6% on the Nifty 50 index. The plan includes a 100% tariff on imports starting August 1, 2028, and a 200% tariff by 2029, raising concerns over the impact on Indian drugmakers, who supply affordable generics to the US market. The Nifty Pharma index declined 1.51% to 25,699.45.